Skip to content
Menu

Morgan Stanley Maintains Overweight on Avalyn Pharma, Lowers Price Target to $53

Benzinga Newsdesk 14 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and lowers the price target from $57 to $53.

Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and lowers the price target from $57 to $53.

Read at benzinga.com